Kodiak Sciences is trading at $80.99, down 5.55% in pre-market, with sector weakness the likeliest explanation; no company-specific catalyst has been confirmed.
- Biotech ETF XBI was down 3.65% pre-market.
- No new company-specific announcement explaining the October 19 decline surfaced in the search; prior clinical and analyst news is background, not a confirmed catalyst.
- Kodiak Sciences closed October 16 at $85.75; the pre-market price is below that close.